Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 20
Filtrar
2.
Rev Esp Quimioter ; 36(3): 302-309, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-36951688

RESUMEN

OBJECTIVE: To determine susceptibility to the novel ß-lactam/ß-lactamase inhibitor combination imipenem/relebactam in clinical isolates recovered from intra-abdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream (BSI) infections in the SMART (Study for Monitoring Antimicrobial Resistance Trends) study in SPAIN during 2016 - 2020. METHODS: Broth microdilution MICs for imipenem/relebactam and comparators were determined by a central laboratory against isolates of Enterobacterales and Pseudomonas aeruginosa. MICs were interpreted using EUCAST-2021 breakpoints. RESULTS: In total, 5,210 Enterobacterales and 1,418 P. aeruginosa clinical isolates were analyzed. Imipenem/relebactam inhibited 98.8% of Enterobacterales. Distinguishing by source of infection susceptibility was 99.1% in BSI, 99.2% in IAI, 97.9% in RTI, and 99.2% in UTI. Of intensive care unit isolates (ICU) 97.4% were susceptible and of non-ICU isolates 99.2% were susceptible. In Enterobacterales, activity against Class A, Class B and Class D carbapenemases was 96.2%, 15.4% and 73.2%, respectively. In P. aeruginosa, imipenem/relebactam was active in 92.2% of isolates. By source of infection it was 94.8% in BSI, 92.9% in IAI, 91.7% in RTI, and 93.1% in UTI. An 88.7% of ICU isolates and 93.6% of non-ICU isolates were susceptible to imipenem/relebactam. Imipenem/relebactam remained active against P. aeruginosa ceftazidime-resistant (76.3%), cefepime-resistant (73.6%), imipenem-resistant (71.5%) and piperacillin-resistant (78.7%) isolates. Of all multidrug-resistant or difficult-to-treat resistance P. aeruginosa isolates, 75.1% and 46.2%, respectively, were susceptible to imipenem/relebactam. CONCLUSIONS: Imipenem/relebactam showed high rates of susceptibility in Enterobacterales and P. aeruginosa isolates from different sources of infection as well as depending on patients' location (ICU or non-ICU scenarios).


Asunto(s)
Infecciones por Pseudomonas , Pseudomonas aeruginosa , Humanos , España/epidemiología , Antibacterianos/farmacología , Imipenem/farmacología , Inhibidores de beta-Lactamasas/farmacología , Pruebas de Sensibilidad Microbiana
3.
Rev Esp Quimioter ; 34(3): 228-237, 2021 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-33645948

RESUMEN

OBJECTIVE: To analyse the susceptibility to ceftolozane-tazobactam and comparators in Enterobacterales and Pseudomonas aeruginosa isolates recovered from intraabdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream infection (BSI) in the SMART (Study for Monitoring Antimicrobial Resistance Trends) study. METHODS: The susceptibility of 5,351 isolates collected in 11 Spanish hospitals (2016-2018) were analysed (EUCAST-2020 criteria) by broth microdilution and were phenotypically studied for the presence of extended-spectrum beta-lactamases (ESBL). Ceftolozane-tazobactam and/or carbapenem resistant isolates were genetically characterized for ESBL and carbapenemases. RESULTS: Escherichia coli was the most frequent pathogen (49.3% IAI, 54.9% UTI, 16.7% RTI and 50% BSI), followed by Klebsiella pneumoniae (11.9%, 19.1%, 13.1% and 15.4%, respectively). P. aeruginosa was isolated in 9.3%, 5.6%, 32% and 9%, respectively. The frequency of isolates with ESBLs (2016-2017) was: 30.5% K. pneumoniae, 8.6% E. coli, 2.3% Klebsiella oxytoca and 0.7% Proteus mirabilis. Ceftolozane-tazobactam was very active against non-ESBL-(99.3% susceptible) and ESBL-(95.2%) producing E. coli being less active against K. pneumoniae (98% and 43.1%, respectively) isolates. CTX-M-15 was the most prevalent ESBL in E. coli (27.5%) and K. pneumoniae (51.9%) frequently associated with OXA-48-like carbapenemase. Overall, 93% of P. aeruginosa isolates were susceptible to ceftolozane-tazobactam, preserving this activity (>75%) in isolates resistant to other beta-lactams except in those resistant to meropenen or ceftazidime-avibactam. GES-5, PER-1, VIM-1/2 were the most prevalent enzymes in isolates resistant to ceftolozane-tazobactam. CONCLUSIONS: Ceftolozane-tazobactam showed high activity rates against isolates recovered in the SMART study although it was affected in K. pneumoniae and P. aeruginosa isolates with ESBL and/or carbapenemases.


Asunto(s)
Infecciones por Pseudomonas , Pseudomonas aeruginosa , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Cefalosporinas/farmacología , Farmacorresistencia Bacteriana , Escherichia coli , Humanos , Pruebas de Sensibilidad Microbiana , Infecciones por Pseudomonas/tratamiento farmacológico , Infecciones por Pseudomonas/epidemiología , España/epidemiología , Tazobactam
4.
Rev Esp Quimioter ; 32(2): 145-155, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-30761824

RESUMEN

OBJECTIVE: Continuous antimicrobial resistance surveillance is recommended by Public Health authorities. We up-dated data from the SMART (Study for Monitoring Antimicrobial Resistance Trends) surveillance study in Spain. METHODS: The antimicrobial susceptibility data and extended-spectrum beta-lactamase (ESBL) production in isolates recovered from intra-abdominal (IAI) (n=1,429) and urinary tract (UTI) (n=937) infections during the 2016- 2017 SMART study in 10 Spanish hospitals were analysed. RESULTS: Escherichia coli was the most frequently microorganism isolated (48.3% and 53.7%) followed by Klebsiella spp. (11.5% and 21.9%) in IAIs and UTIs, respectively. Figures for Pseudomonas aeruginosa were 9.0% and 6.1%, being more frequently recovered from patients with nosocomial infections. Overall, 9.9% (IAI) and 14.0% (UTI) of E. coli, Klebsiella spp. and Proteus mirabilis isolates were ESBL-producers, being Klebsiella pneumoniae (34.5%) from UTI of nosocomial origin the most frequent. ESBL-producers were higher in patients >60 years in both IAIs and UTIs. As in previous years, amikacin (96.3%-100% susceptibility), ertapenem (84.2%-100%) and imipenem (70.3%- 100%) were the most active antimicrobials tested among Enterobacterales species. The activity of amoxicillin-clavulanic, piperacillin-tazobactam, and ciprofloxacin susceptibility was lower, particularly among ESBL-producers. Ertapenem susceptibility (88.9%-100%) was retained in ESBL-E. coli isolates that were resistant to these antimicrobials but decreased (28.6%-100%) in similar isolates of K. pneumoniae. CONCLUSIONS: Continuous antimicrobial resistance surveillance from the SMART study reveals overall maintenance of ESBL-producers in Spain, although with higher presence in isolates from UTIs than from IAIs. Moreover, ertapenem activity was high in E. coli irrespective of ESBL production but decreased in K. pneumoniae, particularly among ESBL-producers.


Asunto(s)
Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Bacterias Gramnegativas/efectos de los fármacos , Infecciones por Bacterias Gramnegativas/tratamiento farmacológico , Infecciones por Bacterias Gramnegativas/microbiología , Infecciones Intraabdominales/tratamiento farmacológico , Infecciones Intraabdominales/microbiología , Infecciones Urinarias/tratamiento farmacológico , Infecciones Urinarias/microbiología , Adulto , Anciano , Infección Hospitalaria/tratamiento farmacológico , Farmacorresistencia Bacteriana/efectos de los fármacos , Farmacorresistencia Bacteriana/genética , Femenino , Infecciones por Bacterias Gramnegativas/epidemiología , Humanos , Infecciones Intraabdominales/epidemiología , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Vigilancia de la Población , España/epidemiología , Infecciones Urinarias/epidemiología , beta-Lactamasas/genética , beta-Lactamasas/metabolismo
5.
J Hosp Infect ; 102(1): 108-115, 2019 May.
Artículo en Inglés | MEDLINE | ID: mdl-30448277

RESUMEN

BACKGROUND: Staphylococcus aureus meningitis is an uncommon nosocomial infection usually associated with neurosurgical procedures, but spontaneous infections may occasionally appear. AIMS: To compare the features of meningitis caused by meticillin-resistant (MRSA) and meticillin-susceptible (MSSA) S. aureus and examine the prognostic factors for mortality, including MRSA infection and combined antimicrobial therapy. METHODS: Retrospective cohort study of 350 adults with S. aureus meningitis admitted to 11 hospitals in Spain (1981-2015). Logistic regression and propensity score matching were used to analyse prognostic factors. RESULTS: There were 118 patients (34%) with MRSA and 232 (66%) with MSSA. Postoperative infection (91% vs 73%) and nosocomial acquisition (93% vs 74%) were significantly more frequent in MRSA than in MSSA meningitis (P < 0.001). Combined therapy was given to 118 (34%) patients. Overall 30-day mortality rate was 23%. On multivariate analysis, mortality was associated with severe sepsis or shock (odds ratio (OR) 9.9, 95% confidence interval (CI) 4.5-22.0, P < 0.001), spontaneous meningitis (OR 4.2, 95% CI 1.9-9.1, P < 0.001), McCabe-Jackson score rapidly or ultimately fatal (OR 2.8, 95% CI 1.4-5.4, P = 0.002), MRSA infection (OR 2.6, 95% CI 1.3-5.3, P = 0.006), and coma (OR 2.6, 95% CI 1.1-6.1, P < 0.029). In postoperative cases, mortality was related to retention of cerebrospinal devices (OR 7.9, 95% CI 3.1-20.3, P < 0.001). CONCLUSIONS: Clinical and epidemiological differences between MRSA and MSSA meningitis may be explained by the different pathogenesis of postoperative and spontaneous infection. In addition to the severity of meningitis and underlying diseases, MRSA infection was associated with increased mortality. Combined antimicrobial therapy was not associated with increased survival.


Asunto(s)
Infección Hospitalaria/epidemiología , Meningitis Bacterianas/epidemiología , Resistencia a la Meticilina , Infecciones Estafilocócicas/epidemiología , Staphylococcus aureus/efectos de los fármacos , Staphylococcus aureus/aislamiento & purificación , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antibacterianos/uso terapéutico , Infección Hospitalaria/microbiología , Infección Hospitalaria/mortalidad , Infección Hospitalaria/patología , Femenino , Hospitales , Humanos , Masculino , Meningitis Bacterianas/microbiología , Meningitis Bacterianas/mortalidad , Meningitis Bacterianas/patología , Persona de Mediana Edad , Pronóstico , Estudios Retrospectivos , España/epidemiología , Infecciones Estafilocócicas/microbiología , Infecciones Estafilocócicas/mortalidad , Infecciones Estafilocócicas/patología , Análisis de Supervivencia , Adulto Joven
6.
Rev Esp Quimioter ; 31(5): 439-442, 2018 Oct.
Artículo en Español | MEDLINE | ID: mdl-30251525

RESUMEN

OBJECTIVE: Kingella kingae is a common colonizer of the oropharynx in children that may lead to invasive infection, mainly osteoarticular infections. Invasive infections occur almost exclusively in young children, fundamentally fewer than two years old. K. kingae infections in children are probably underdiagnosed due to the difficulty in growing in routine cultures and the absence of systematic realization of molecular techniques to identify it. It is the most common bacteria involved in childhood osteoarticular infections in recent series and increasingly being recognized in Spain. We report our experience on the epidemiological and clinical characteristics of osteoarticular infections in children in recent years. METHODS: Retrospective analysis of septic arthritis by K. kingae identified by PCR in joint fluid in children during 2010-2016. Epidemiological, clinical and laboratory characteristics are presented. RESULTS: Five arthritis by K. kingae were identified, all of them in ≤6 years old children. Median leukocytes, CRP and ESR were 12950 leukocytes/µL, 4.84 mg/dL and 58 mm/h respectively, and 61,322 leukocytes /µL in joint fluid. All patients evolved favorably. CONCLUSIONS: Osteoarticular infections by K. kingae in children usually present low increase of inflammatory markers despite being invasive infections. The development of PCR in sterile samples has greatly improved the diagnostic yield of K. kingae infections improving the management of osteoarthritis in children.


Asunto(s)
Artritis Infecciosa/etiología , Artritis Infecciosa/microbiología , Kingella kingae , Infecciones por Neisseriaceae/complicaciones , Infecciones por Neisseriaceae/microbiología , Líquidos Corporales/microbiología , Niño , Preescolar , Femenino , Humanos , Lactante , Articulaciones , Masculino , Osteomielitis/microbiología , Reacción en Cadena de la Polimerasa , Estudios Retrospectivos
7.
Rev Esp Quimioter ; 31(2): 136-145, 2018 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-29532655

RESUMEN

OBJECTIVE: The SMART (Study for Monitoring Antimicrobial Resistance Trends) surveillance study monitors antimicrobial susceptibility and extended spectrum ß-lactamases (ESBLs) in Gram-negative bacilli recovered from intra-abdominal infections (IAI). METHODS: Antimicrobial susceptibility of 5,343 isolates from IAI recovered in 11 centres during the 2011-2015 SMART-Spain program was analysed by standard microdilution (EUCAST criteria) and compared with that from 2002-2010. ESBLs were phenotypically detected. RESULTS: Escherichia coli, the most common isolate, significantly decreased in community acquired IAI (60.9% 2002-2010 vs. 56.1% 2011-2015, P=0.0003). It was followed in prevalence by Klebsiella pneumoniae that increased both in the community (8.9% vs. 10.8%, P=0.016) and nosocomial (9.2% vs. 10.8%, P=0.029) IAI and P. aeruginosa, which significantly increased in community acquired IAI (5.6% vs. 8.0%, P=0.0003). ESBLs were more prevalent in K. pneumoniae (16.3%) than in E. coli (9.5%) of nosocomial origin and were more frequently isolated from elderly patients (>60 years). Considering all Enterobacteriaceae, ertapenem (92.3-100%) and amikacin (95.5%-100%) were the most active antimicrobials. Ertapenem activity, unlike amoxicillin-clavulanate or piperacillin-tazobactam, remained virtually unchanged in ESBL (100%) and non-ESBL (98.8%) E. coli producers. Its activity decreased in ESBL-K. pneumoniae (74.7%) but was higher than that of amoxicillin-clavulanate (14.0%) and piperacillin-tazobactam (24.0%). Interestingly, ertapenem susceptibility was maintained in >60% of ESBL isolates that were resistant to amoxicillin-clavulanate, piperacillin-tazobactam or fluoroquinolones. CONCLUSIONS: SMART-Spain results support current guidelines which include ertapenem as empiric treatment in mild-moderate community-acquired IAI, particularly with ESBL producers. These recommendations will need to be updated with the recently introduction of new antimicrobials.


Asunto(s)
Bacterias Gramnegativas/efectos de los fármacos , Infecciones por Bacterias Gramnegativas/microbiología , beta-Lactamasas/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Infección Hospitalaria/microbiología , Combinación de Medicamentos , Ertapenem , Escherichia coli/efectos de los fármacos , Femenino , Infecciones por Bacterias Gramnegativas/tratamiento farmacológico , Humanos , Klebsiella pneumoniae/efectos de los fármacos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Prevalencia , España/epidemiología , beta-Lactamasas/análisis , beta-Lactamas/farmacología , beta-Lactamas/uso terapéutico
8.
Rev Esp Quimioter ; 30(2): 142-168, 2017 Apr.
Artículo en Español | MEDLINE | ID: mdl-28198169

RESUMEN

Invasive pneumococcal disease (IPD) and pneumococcal pneumonia (PP) represent an important health problem among aging adults and those with certain underlying pathologies and some diseases, especially immunosuppressed and some immunocompetent subjects, who are more susceptible to infections and present greater severity and worse evolution. Among the strategies to prevent IPD and PP, vaccination has its place, although vaccination coverage in this group is lower than desirable. Nowadays, there are 2 vaccines available for adults. Polysacharide vaccine (PPV23), used in patients aged 2 and older since decades ago, includes a greater number of serotypes (23), but it does not generate immune memory, antibody levels decrease with time, causes an immune tolerance phenomenon, and have no effect on nasopharyngeal colonization. PCV13 can be used from children 6 weeks of age to elderly and generates an immune response more powerful than PPV23 against most of the 13 serotypes included in it. In the year 2013 the 16 most directly related to groups of risk of presenting IPD publised a series of vaccine recommendations based on scientific evidence regarding anti-pneumococcal vaccination in adults with underlying pathologies and special conditions. A commitment was made about updating it if new scientific evidence became available. We present an exhaustive revised document focusing mainly in recommendation by age in which some more Scientific Societies have been involved.


Asunto(s)
Infecciones Neumocócicas/prevención & control , Vacunas Neumococicas , Adulto , Anciano , Niño , Preescolar , Consenso , Humanos , Neumonía Neumocócica/prevención & control , Streptococcus pneumoniae , Vacunación
9.
Rev. esp. med. prev. salud pública ; 22(1/2): 32-37, 2017. graf, tab
Artículo en Español | IBECS | ID: ibc-166235

RESUMEN

En el año 2013 algunas de las Sociedades Científicas más directamente relacionadas con los grupos de riesgo para padecer enfermedad neumocócica publicamos un documento de Consenso con una serie de recomendaciones basadas en las evidencias científicas respecto a la vacunación antineumocócica en el adulto con condiciones especiales y patología de base. Se estableció un compromiso de discusión y actualización ante la aparición de nuevas evidencias. Fruto de este trabajo de revisión, en abril de 2017 se ha publicado una actualización del anterior documento junto a 4 nuevas Sociedades Científicas donde destaca, entre otras novedades, la recomendación de vacunación por criterio de edad. Se resumen algunas de las principales novedades que presenta la actualización del documento de Consenso


In the year 2013 some of the most directly related to groups of risk of presenting IPD Scientific Societies published a series of vaccine recommendations based on scientific evidence regarding anti-pneumococcal vaccination in adults with underlying pathologies and special conditions. A commitment was made about updating it if new scientific evidence became available. In april 2017 an exhaustive revision over the previous document was published focusing mainly in recommendation by age. We review some of the main changes in the new Consensus document


Asunto(s)
Humanos , Adulto , Vacunas Neumococicas/administración & dosificación , Infecciones Neumocócicas/prevención & control , Bacteriemia/prevención & control , Enfermedad Crónica/epidemiología , Grupos de Riesgo
11.
Clin Microbiol Infect ; 21(7): 684.e1-9, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-25765773

RESUMEN

We aimed to develop a simple prediction score to identify fluconazole non-susceptible (Flu-NS) candidaemia using simple clinical criteria. A derivation cohort was extracted from the CANDIPOP study, a prospective, multicentre, population-based surveillance programme on candidaemia conducted in 29 hospitals in Spain from April 2010 to May 2011. The score was validated with an external, multicentre cohort of adults with candidaemia in six tertiary hospitals in three countries. The prediction score was based on three variables selected by a logistic regression model together with the severity of disease. In total, 617 and 297 cases of candidaemia were included in the derivation and validation cohorts, respectively; of these, 134 (21.7%) and 57 (19.2%) were caused by Flu-NS strains. Factors independently associated with Flu-NS were transplant recipient status (adjusted odds ratio (AOR) 2.13; 95% CI 1.01-4.55; p 0.047), hospitalization in a unit with a high prevalence (≥ 15%) of Flu-NS strains (7.53; 4.68-12.10; p < 0.001), and previous azole therapy for at least 3 days (2.04; 1.16-3.62; p 0.014). The area under the receiver operating characteristics curve (AUC) was 0.76 (0.72-0.81), and using 2 points as the Flu-NS prediction score cut-off gave a sensitivity of 82.1%, a specificity of 65.6%, and a negative predictive value of 93%. The AUC in the validation cohort was 0.72 (95% CI 0.65-0.79). Hence, the Flu-NS prediction score helped to exclude Flu-NS Candida strains. This could improve the selection of empirical treatments for candidaemia in the future.


Asunto(s)
Antifúngicos/farmacología , Candida/efectos de los fármacos , Candidemia/epidemiología , Técnicas de Apoyo para la Decisión , Fluconazol/farmacología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Candidemia/microbiología , Femenino , Hospitales , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Curva ROC , Medición de Riesgo , España/epidemiología , Adulto Joven
12.
Rev Esp Quimioter ; 25(3): 226-39, 2012 Sep.
Artículo en Español | MEDLINE | ID: mdl-22987273

RESUMEN

Health care workers (HCW) are included each year among risk groups for vaccination against influenza. However, vaccination coverage among this group in our country is very low, not exceeding 25%. Convinced that one of the best tools to increase this coverage among professionals in our country are the scientific evidence, 19 scientific societies and associations professionals bringing together health professionals more directly related to influenza as an health problem, and the General Nursing Council, met to discuss and develop this consensus document in order to inform HCW about the appropriateness of their vaccination against influenza and the benefits that flow from it for themselves, for their patients and for the rest of the population. This recommendation is based on 3 pillars: argument of necessity, ethics and exemplary.


Asunto(s)
Personal de Salud , Gripe Humana/prevención & control , Vacunación/normas , Consenso , Guías como Asunto , Personal de Salud/ética , Humanos , Vacunas contra la Influenza , España/epidemiología , Vacunación/ética
13.
Rev. esp. quimioter ; 22(4): 221-223, dic. 2009. ilus
Artículo en Español | IBECS | ID: ibc-75214

RESUMEN

Las infecciones por mordedura de animal son muy comunesen nuestro medio. Las más frecuentes están producidaspor animales domésticos. De todas ellas, la que con mas frecuenciaproduce contagios es la de gato y a menudo por especiesdel genero Pasteurella sp. Presentamos dos casos de infecciónpor P multocida tras mordedura de gato. Además, enel presente artículo se revisan los principales cuadros clínicosrelacionados con esta etiología y algunos aspectos de sensibilidadfrente a antimicrobianos(AU)


Animal bite wounds are common. Domestic companionanimals inflict the majority of these wounds. Themost important percentage of contagions are due to catbites, and often by Pasteurella species. We present twocases of Pasteurella multocida infection after a cat bite.Thus, in this article we review the most relevant clinicalfeatures related with this aetiological agent and some aspectsabout antimicrobial susceptibility(AU)


Asunto(s)
Humanos , Femenino , Adulto , Persona de Mediana Edad , Celulitis/complicaciones , Celulitis/diagnóstico , Enfermedades de los Gatos/diagnóstico , Enfermedad por Rasguño de Gato/complicaciones , Medios de Cultivo/aislamiento & purificación , Cefalosporinas/uso terapéutico , Tetraciclina/uso terapéutico , Cloranfenicol/uso terapéutico , Celulitis/microbiología , Celulitis/virología , Fiebre/complicaciones , Fiebre/etiología , Agar/análisis
14.
Rev Esp Quimioter ; 22(4): 221-3, 2009 Dec.
Artículo en Español | MEDLINE | ID: mdl-20082044

RESUMEN

Animal bite wounds are common. Domestic companion animals inflict the majority of these wounds. The most important percentage of contagions are due to cat bites, and often by Pasteurella species. We present two cases of Pasteurella multocida infection after a cat bite.Thus, in this article we review the most relevant clinical features related with this aetiological agent and some aspects about antimicrobial susceptibility.


Asunto(s)
Mordeduras y Picaduras/complicaciones , Celulitis (Flemón)/etiología , Infecciones por Pasteurella/etiología , Animales , Antibacterianos/uso terapéutico , Gatos , Femenino , Humanos , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Infecciones por Pasteurella/microbiología , Pasteurella multocida/efectos de los fármacos , Adulto Joven
16.
Emergencias (St. Vicenç dels Horts) ; 17(1): s7-s12, feb. 2005.
Artículo en Es | IBECS | ID: ibc-038243

RESUMEN

El mecanismo patogénico de la exacerbación de la EPOC no es bien conocido por las dificultades para utilizar técnicas agresivas durante los episodios. Se trata de un complejo proceso inflamatorio en el que la infección parece ser la responsable de hasta el 70- 80% de los episodios. Las bacterias se aíslan en el 40-60% de los cultivos de esputo de estos enfermos, encontrándose, sobre todo, Haemophilus influenzae, Streptococcus pneumoniae y Moraxella catarrhalis. En pacientes con EPOC basal más grave se pueden aislar también Pseudomonas aeruginosa, Haemophilus parainfluenzae y enterobacterias. Cada vez se aíslan con más frecuencia bacterias atípicas, especialmente Chlamydia pneumoniae, que además puede permanecer de forma indefinida, jugando un papel en el mantenimiento de la inflamación bronquial. Los virus pueden ser responsables del 30% de las exacerbaciones y favorecen la infección bacteriana. Los principales virus implicados son ARN (rhinovirus, influenza, parainfluenza, coronavirus y virus respiratorio sinticial) y menos virus ADN (adenovirus y citomegalovirus). Se discuten los mecanismos patogénicos por los que los microorganismos pueden dar lugar a la exacerbación y las evidencias que existen de ello (AU)


Role of infection in chronic obstructive pulmonary disease (COPD) exacerbations The pathogenetic mechanism of chronic obstructive pulmonary disease (COPD) exacerbation is not fully known because of the difficulties implicit in the use of aggressive techniques and procedures in the course of acute episodes. In general terms, it is a complex inflammatory event in which infection appears to be responsible for up to 70 or 80% of the episodes. Bacteria are isolated in 40-60% of the sputum cultures of these patients, with predominance of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. In patients with more severe baseline COPD, Pseudomonas aeruginosa, Haemophilus parainfluenzae and enterobacteriae may also be isolated. Atypical bacteria are isolated with increasing frequence, particularly Chlamydia pneumoniae, which may furthermore persist indefinitely and play a significant role in the maintenance of bronchial inflammation. Viruses may be responsible in up to 30% of exacerbations and they favour bacterial infection. The main involved viruses are of the RNA type (rhinovirus, influenzavirus, parainfluenzavirus, coronavirus and Respiratory Syncitial virus) and, to a lesser extent, DNA viruses (adenovirus and cytomegalovirus). The pathogenetic mechanisms whereby microorganisms may cause exacerbation are discussed, together with the supporting evidence (AU)


Asunto(s)
Humanos , Infecciones del Sistema Respiratorio/complicaciones , Enfermedad Pulmonar Obstructiva Crónica/complicaciones , Recurrencia , Bacterias/patogenicidad , Virus/patogenicidad
17.
Rev. esp. quimioter ; 16(4): 428-435, dic. 2003.
Artículo en Es | IBECS | ID: ibc-29350

RESUMEN

La finalidad de este estudio fue conocer el enfoque terapéutico y la tendencia de las infecciones por grampositivos, en los hospitales españoles, en lo referente a prevalencia, origen, localización y etiología, así como las características de los pacientes, enfermedades de base, gravedad y factores predisponentes. Se compararon, mediante análisis estadístico, los resultados de dos estudios de prevalencia multicéntricos, de 1994-1995 el primero y de 1998 el segundo. Encontramos un descenso estadísticamente significativo en el porcentaje de pacientes infectados (45,8 por ciento vs. 32,8 por ciento; p <0.001), pero un aumento en el de infección por grampositivos (14,4 por ciento vs. 20,6 por ciento; p <0.001), que se refleja en el aumento del empleo de glucopéptidos (17,1 por ciento vs. 31,2 por ciento; p = 0.002). También aumentó el uso de quinolonas. Las enfermedades de base más frecuentes fueron cardiopatías y diabetes mellitus; se observó una disminución del número de pacientes infectados por el virus de la inmunodeficiencia humana y de usuarios de drogas por vía parenteral. El descenso de la infección extrahospitalaria convirtió la nosocomial en la más frecuente en el segundo estudio, en el cual aumentó la presencia de factores predisponentes (52,3 por ciento vs. 79,2 por ciento; p <0.001), siendo los más comunes vía periférica, inmovilización y sonda vesical. La bacteriemia se mantuvo como infección más frecuente, disminuyendo las infecciones de vías respiratorias bajas y aumentando las de piel y tejidos blandos. El microorganismo más frecuente y en significativo aumento fue Staphylococcus aureus (27,2 por ciento vs. 47,9 por ciento; p <0.001), mientras que la incidencia del neumococo disminuyó (15,0 por ciento vs. 5,2 por ciento; p = 0.012). Se concluye que, a pesar del descenso en el porcentaje de infectados y en la gravedad, queda patente la tendencia al aumento de las infecciones por grampositivos, principalmente bacteriemia, y a combatirlos con tratamientos más agresivos, que pueden reflejar el aumento de aislamientos resistentes (AU)


Asunto(s)
Femenino , Persona de Mediana Edad , Masculino , Humanos , Medicina Interna , Prevalencia , Infecciones por Bacterias Grampositivas , España , Hospitales
19.
Eur J Intern Med ; 14(5): 341-343, 2003 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-13678763

RESUMEN

Foot ulcers and infections are common in diabetic patients. A 30-month-long descriptive study was conducted in our hospital in which we analyzed microbiological isolates of all patients admitted with diabetic foot infections. The predominant flora identified were Staphylococcus aureus and coagulase-negative Staphylococcus, followed by Enterococcus spp., Streptococcus spp., and enterobacteriaceaes. In 27 positive cultures (42%) polymicrobial flora were found. There were only 5% anaerobic bacteria. There appears to be a relationship between the sample collection system and microbiological isolates.

20.
Rev Esp Quimioter ; 16(4): 428-35, 2003 Dec.
Artículo en Español | MEDLINE | ID: mdl-14961137

RESUMEN

This study aimed to identify therapeutic approaches and the tendencies of Gram-positive infections in Spanish hospitals in terms of prevalence, origin, location and etiology, as well as the characteristics of patients with these infections, their underlying illnesses, the severity and predisposing factors. We used statistical analysis to compare the results of two multicenter prevalence studies, the first from 1994-1995, and the second in 1998. We found a statistically significant decrease in the percentage of infected patients (45.8% vs. 32.8%; p <0.001), but an increase in infections by Gram-positive microorganisms (14.4% vs. 20.6%; p <0.001), which was reflected in the increased use of glycopeptides (17.1% vs. 31.2%; p = 0.002). The use of quinolones also increased. The most common underlying illnesses were heart disease and diabetes mellitus, and there was a reduction in the number of patients infected by HIV and in users of parenteral medication. The decrease in outpatient infections indicated that nosocomial infection was more frequent in the second study, in which the number of predisposing factors increased (52.3% vs. 79.2%; p <0.001), the most common of which were peripheral line, immobilization and a bladder catheter. Bacteremia was the most frequent infection, and there was a reduction in lower respiratory tract infections and an increase in skin and soft tissue infections. Staphylococcus aureus was the most frequently found microorganism and showed a significant increase in incidence (27.2% vs. 47.9%; p <0.001), whereas pneumococcus showed a decrease (15.0% vs. 5.2%; p = 0.012). It was concluded that despite the decrease in the percentage of infected patients and severely ill patients, there is an increase in Gram-positive infections, especially bacteremia, and in the use of more aggressive treatments. This may reflect the increase in resistant isolates.


Asunto(s)
Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Infecciones por Bacterias Grampositivas/epidemiología , Femenino , Hospitales , Humanos , Medicina Interna , Masculino , Persona de Mediana Edad , Prevalencia , España
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...